OPHN1

Oligophrenin-1 is a protein that in humans is encoded by the OPHN1 gene.[5][6][7]

OPHN1
Identifiers
AliasesOPHN1, ARHGAP41, MRX60, OPN1, oligophrenin 1
External IDsOMIM: 300127 MGI: 2151070 HomoloGene: 1913 GeneCards: OPHN1
Gene location (Human)
Chr.X chromosome (human)[1]
BandXq12Start68,042,344 bp[1]
End68,433,913 bp[1]
Orthologs
SpeciesHumanMouse
Entrez

4983

94190

Ensembl

ENSG00000079482

ENSMUSG00000031214

UniProt

O60890

Q99J31

RefSeq (mRNA)

NM_002547

NM_052976
NM_001313754
NM_001313755
NM_001313756

RefSeq (protein)

NP_002538

NP_001300683
NP_001300684
NP_001300685
NP_443208

Location (UCSC)Chr X: 68.04 – 68.43 MbChr X: 98.55 – 98.89 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Function

Oligophrenin 1 has 25 exons and encodes a Rho-GTPase-activating protein. The Rho protein are important mediators of intracellular signal transduction, which affects cell migration and cell morphogenesis.

Clinical significance

Mutations in this gene are responsible for non-specific X-linked intellectual disability (previously called mental retardation).[7]

OPHN1 syndrome is a rare disorder characterized by intellectual disability and changes in the part of the brain which controls movement and balance (cerebellum). The syndrome mainly affects males. It is characterized by low muscle tone (hypotonia), developmental and cognitive delay, early-onset seizures, abnormal behavior, characteristic facial features (long face, bulging forehead, under eye creases, deep set eyes, and large ears), crossed eyes (strabismus) and inability to coordinate movements.[8] [9] A small cerebellum and large ventricles can be seen on brain imaging (MRI).[8][10][11] Treatment is supportive and includes physical, occupational and speech and language therapy.[12] In 2014 an OPHN1 patient organization and website was formed to support families and promote OPHN1 syndrome research. [13]

OPHN1 syndrome is caused by mutations in the OPHN1 gene, which is located on the X chromosome. Inheritance is X-linked.[8] Some females who carry a mutation in the OPHN1 gene may have mild learning disabilities, mild cognitive impairment, strabismus, and subtle facial changes.[7]

References

  1. GRCh38: Ensembl release 89: ENSG00000079482 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000031214 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Bienvenu T, Der-Sarkissian H, Billuart P, Tissot M, Des Portes V, Brüls T, Chabrolle JP, Chauveau P, Cherry M, Kahn A, Cohen D, Beldjord C, Chelly J, Cherif D (Aug 1997). "Mapping of the X-breakpoint involved in a balanced X;12 translocation in a female with mild mental retardation". European Journal of Human Genetics. 5 (2): 105–9. doi:10.1159/000484743. PMID 9195162.
  6. Billuart P, Bienvenu T, Ronce N, des Portes V, Vinet MC, Zemni R, Roest Crollius H, Carrié A, Fauchereau F, Cherry M, Briault S, Hamel B, Fryns JP, Beldjord C, Kahn A, Moraine C, Chelly J (April 1998). "Oligophrenin-1 encodes a rhoGAP protein involved in X-linked mental retardation". Nature. 392 (6679): 923–6. Bibcode:1998Natur.392..923B. doi:10.1038/31940. PMID 9582072.
  7. "Entrez Gene: OPHN1 oligophrenin 1".
  8. Zanni G, Bertini ES (May 2011). "X-linked disorders with cerebellar dysgenesis". Orphanet Journal of Rare Diseases. 6: 24. doi:10.1186/1750-1172-6-24. PMC 3115841. PMID 21569638.
  9. "OPHN1". Genetics Home Reference. 2016.
  10. Zanni, Ginevra (February 2013). "X-linked intellectual disability-cerebellar hypoplasia syndrome". Orphanet.
  11. Bedeschi MF, Novelli A, Bernardini L, Parazzini C, Bianchi V, Torres B, Natacci F, Giuffrida MG, Ficarazzi P, Dallapiccola B, Lalatta F (July 2008). "Association of syndromic mental retardation with an Xq12q13.1 duplication encompassing the oligophrenin 1 gene". American Journal of Medical Genetics. Part A. 146A (13): 1718–24. doi:10.1002/ajmg.a.32365. PMID 18512229.
  12. "OPHN1 therapies". Oligophrenin-1 Syndrome Foundation.
  13. "OPHN1 therapies". Oligophrenin-1 Syndrome Foundation.

Further reading

 This article incorporates public domain material from the National Institutes of Health document: "OPHN1 syndrome".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.